Pharmacy World and Science

, Volume 19, Issue 1, pp 1–12 | Cite as

Part 1: Neuromuscular transmission and general aspects of its blockade

  • L.H.D.J. Booij


Blockade of neuromuscular transmission is an important feature during anaesthesia and intensive care treatment of patients. The neuromuscular junction exists in a prejunctional part where acetylcholine is synthesized, stored and released in quanta via a complicated vesicular system. In this system a number of proteins is involved. Acetylcholine diffuses across the junctional cleft and binds to acetylcholinereceptors at the postjunctional part, and is thereafter metabolized by acetylcholinesterase in the junctional cleft. Binding of acetylcholine to its postjunctional receptor evokes muscle contraction. Normally a large margin of safety exists in the neuromuscular transmission. In various situations, apart from up‐and‐down regulation of acetylcholine receptors, adjustment of acetylcholine release can occur.

Pharmacological interference can interrupt the neuromuscular transmission and causes muscle relaxation. For this reason both depolarizing and non‐depolarizing muscle relaxants are clinically used. The characteristics of an ideal clinical muscle relaxant are defined. In the description of the pharmacology of the relaxants the importance of pharmacodynamic and pharmacokinetic parameters are defined. Stereoisomerism plays a role with the relaxants. Toxins and venoms also interfere with neuromuscular transmission, through both pre‐and postjunctional mechanisms.

Muscle relaxants Neuromuscular junction Neuromuscular blockade Neurotoxins Pharmacokinetics Pharmacodynamics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Desaki J, Uehara Y. The overall morphology of neuromuscular junctions as revealed by scanning electron microscopy. J Neurocytol 1981;10:101–10.Google Scholar
  2. 2.
    Jasmin BJ, Lee RK, Rotundo RL. Compartmentalization of acetylcholinesterase mRNA and enzyme at the vertebrate neuromuscular junction. Neuron 1993;11:467–77.Google Scholar
  3. 3.
    Fernandez HL, Donoso JA. Exercise selectively increases G4 Ache activity in fast-twitch muscle. J Appl Physiol 1988;65:2245–52.Google Scholar
  4. 4.
    Massoulié J, Bon S. The molecular forms of cholinesterase and acetylcholinesterase in vertebrates. J Neurosci 1982;5: 1180–7.Google Scholar
  5. 5.
    Taylor P. The cholinesterases. J Biol Chem. 1991;266:4025–8.Google Scholar
  6. 6.
    Massoulié J, Pezzementi L, Bon S, Krejci E, Vallette FM. Molecular and cellular biology of cholinesterase. Prog.Neurobiol. 1993;13:31–91.Google Scholar
  7. 7.
    Wright DL, Plummer DT. Multiple forms of acetylcholinesterase from human erythrocytes. Biochem J 1973;133:521–7.Google Scholar
  8. 8.
    Weiler M, Roed IS, Whittaker VP. The kinectics of acetylcholine turnover in a resting cholinergic nerve terminal and the magnitude of the cytoplasmic compartment. J Neurochem 1982;38:1187–91.Google Scholar
  9. 9.
    Tucek S, Cheng SC. Provenance of the acetyl group of acetylcholine and experimentations of acetyl-CoA and Krebs cycle intermediates in the brain in vivo J Neurochem 1974;22:893–914.Google Scholar
  10. 10.
    Haga T, Noda H. Choline uptake systems of rat brain synaptosomes. Biochem Biophys Acta 1973;291:564–75.Google Scholar
  11. 11.
    Potter LT. Synthesis, storage and release of [ 14 C]acetylcholine in isolated rat diaphragm muscles. J Physiol 1970;206:145–66.Google Scholar
  12. 12.
    Yamamura HI, Snyder SH. Choline: high affinity uptake by rat synaptosomes. Science 1972;178:626–8.Google Scholar
  13. 13.
    Barker LA, Mittag TW. Comparative studies of substrates and inhibitors of choline transport and choline acetyltransferase. J Pharmacol Exp Ther 1975;192:86–94.Google Scholar
  14. 14.
    Tucek S. The synthesis of acetylcholine in skeletal muscles of the rat. J Physiol 1982;322:53–69.Google Scholar
  15. 15.
    Bonner TI, Erikson JD. Molecular biology of the vesicular ACh transporter. Trends Neurosci 1995;18:218–24.Google Scholar
  16. 16.
    Parsons SH, Prior C, Marshall IG. Acetylcholine transport, storage, and release. Int Rev Neurobiol 1993;35:279–390.Google Scholar
  17. 17.
    Searl T, Prior C, Marshall IG. The effects of L-vesamicol, an inhibitor of vesicular acetylcholine uptake, on two populations of miniature endplate currents at the snake neuromuscular junction. Neurosci 1990;35:145–56.Google Scholar
  18. 18.
    Kelly RB. Storage and release of neurotransmitters. Neuron 1993;10:43–53.Google Scholar
  19. 19.
    Fertuck HC, Salpeter MM. Localization of acetylcholine receptor by 1251-labeled a-bungarotoxin binding at mouse motor end-plate. Proc Natl Acad Sci USA 1974;72:1376–8.Google Scholar
  20. 20.
    Daniels MP, Vogel Z. Immunoperoxidase staining of a-bungarotoxin binding sites in muscle end-plates shows distribution of acetylcholine receptors. Nature 1975;254:339–41.Google Scholar
  21. 21.
    Yorifuji H, Hirokawa N. Cytoskeletal architecture of neuromuscular junction: Localization of vesicles. J Electron Microsc Tech 1989;12:160–71.Google Scholar
  22. 22.
    Katz B, Miledi R R. The measurement of synaptic delay, and the time course of acetylcholine release at the neuromuscular junction. Proc R Lond Biol Sci 1965;161:483–95.Google Scholar
  23. 23.
    Katz B, Miledi R. The effect of temperature on the synaptic delay at the neuromuscular junction. J Physiol (Lond.) 1965;181:656–70.Google Scholar
  24. 24.
    Silinsky EM. The biophysical pharmacology of calcium dependent avetylcholine secretion. Pharmacol Rev 1985;37: 81–132.Google Scholar
  25. 25.
    Parnas H, Parnas I, Segel LA. On the contribution of mathematical models to the understanding of neurotransmitter release. Int Rev Neurobiol 1990;32:1–50.Google Scholar
  26. 26.
    Kelly RB. Storage and release of neurotransmitters. Neuron 1993;10:43–53.Google Scholar
  27. 27.
    De Camilli P. Molecular mechanisms in synaptic vesicle recycling. FEBS Letters 1995;369:3–12.Google Scholar
  28. 28.
    Greengard P, Valtorta F, Czernik AJ, Benfenati F. Synaptic vesicle phosphoproteins and regulation of synaptic function. Science 1993;259:780–5.Google Scholar
  29. 29.
    Smith SJ, Buchanan HJ, Ossess LR, Charlton MP, Augustine GJ. The spatial distribution of calcium signals in squid presynaptic terminals. J Physiol 1993;472:573–93.Google Scholar
  30. 30.
    Robitaille R, Adler EM, Charlton MP. Strategic location of calcium channels at transmitter release sites of frog neuromuscular synapses. Neuron1990;5:773–9.Google Scholar
  31. 31.
    Robinson MS. The role of clathrin, adaptors and dynamin in endocytosis. Curr Opin Cell Biol 1994;6:538–44.Google Scholar
  32. 32.
    McPherson P, De Camilli P. Sem.Neurosci. 1994;6:137–47.Google Scholar
  33. 33.
    Fesce R, Grohovaz F, Valtorta F, Meldolesi J. Neurotransmitter release: fusion or ‘kiss-and-run’? Trends Cell Biol 1994;4:1–4.Google Scholar
  34. 34.
    van der Bliek AM, Redelmeier TE, Damke H, Tisdale EJ, Meyerowitz EM, Schmid SL. Mutations in human dynamin block: an intermediate stage in coated vesicle formation. J Cell Biol 1993;122:553–63.Google Scholar
  35. 35.
    Takei K, McPherson P, Schmid SL, DeCamilli P. Tubular membrane invaginations coated by dynamin rings are induced by GTP-g-S in nerve terminals. Nature 1995;374:186–90.Google Scholar
  36. 36.
    Regnier-Vigouroux A, Tooze SA, Huttner WB. Newly synthetized synaptophtysin is transported to synaptic-like microvesicles via constitutive secetrory vesicle and the plasma membrane. EMBO J. 1991;10:3589–601.Google Scholar
  37. 37.
    De Camilli P, Benfenati F, Valtorta F, Greengard P. The synapsins. Ann Rev Cell Biol 1990;6:433–60.Google Scholar
  38. 38.
    Hurlbut WP, Iezzi N, Fesce R, Ceccarelli B. Correlation between quantal secretion and vesicle loss at the frog neuromuscular junction. J Physiol 1990;425:501–26.Google Scholar
  39. 39.
    Khanin R, Parnas H, Segel L. Diffusion cannot given govern the discharge of neurotransmitter in fast synapses. Biophys J 1994;67:966–72.Google Scholar
  40. 40.
    Vizi ES, Vyskocil F. Changes in total and quantal release of acetylcholine in the mouse diaphragm during activation and inhibition of membrane ATPase. J Physiol (Lond.) 1979; 286;1–14.Google Scholar
  41. 41.
    Dunant Y. On the mechanism of acetylcholine release. Progr Neurobiol 1986;26:55–92.Google Scholar
  42. 42.
    Glavonoviç MI, Narahashi T. Depression, recovery and facilitation of neuromuscular transmission during prolonged tetanic stimulation. Neurosci 1988;25:271–81. 9.Google Scholar
  43. 43.
    Weiler M, Roed IS, Whittaker VP. The kinetics of acetylcholine turnover in a resting cholinergic nerve terminal and the magnitude of the cytoplasmic compartment. J Neurochem 1982;38:1187–91.Google Scholar
  44. 44.
    Bowman WC. Prejunctional and postjunctional cholinoreceptors at the neuromuscular junction. Anesth Analg 1980;59:935–43.Google Scholar
  45. 45.
    D'Agostino G, Chiari MC, Grana E, Subissi A, Kilbinger H. Muscarinic inhibition of acetylcholine release from a novel in vitro preparation of the guinea-pig trachea. Naun Schmiedeberg's Arch Pharmacol 1990;342:141–45.Google Scholar
  46. 46.
    Molenaar PC, Polak AL. Stimulation of atropine on acetylcholine release and synthesis in cortical slices from rat brain. Br J Pharmacol 1970;40:406–17.Google Scholar
  47. 47.
    Aas P, Fonnum F. Presynaptic inhibition of acetylcholine release. Acta Physiol Scand 1986;127:335–42.Google Scholar
  48. 48.
    Deneris ES, Connolly J, Rogers SW, Duvoisin R. Pharmacological and functional diversity of neuronal nicotinic actylcholine receptors. Trends Parharmacol Sci 1991; 12:34–40.Google Scholar
  49. 49.
    Wessler I, Halank M, Rasbach J, Kilbinger H. Presynaptic nicotine receptors mediating a positive feedback on transmitter release from the rat phrenic nerves. Naun Schmiedeberg's Arch Pharmacol 1986;334:365–72.Google Scholar
  50. 50.
    Wessler I. Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. Trends Pharmaco Sci 1989;10:110–14.Google Scholar
  51. 51.
    Reynolds J, Karlin A. Molecular weight in detergent solution of acetylcholine receptor from torpedo californica. Biochemistry 1978;17:2035–38.Google Scholar
  52. 52.
    Raftery MA, Hunkapiller MW, Strader CD, Hood LE. Acetylcholine receptor: Complex of homologous subunits. Science 1980;208:1454–57.Google Scholar
  53. 53.
    Martinou JC, Merlie JP. Nerve-dependent modulation of acetylcholine receptor epsilon-subunit gene expression. J Neurosci 1991;11:1291–9.Google Scholar
  54. 54.
    Falls Dl, Rosen Km, Corfas G, Lane WS, Fischbach GD. ARIA, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family. Cell 1993;72:801–15.Google Scholar
  55. 55.
    Sandrock AW, Gosdearl ADJ, Yin Q-W, Chang D, Fischbach GD. ARIA is concentrated in the nerve terminals at neuromuscular junctions and at other synapses. J Neurosci 1995;15:124–36.Google Scholar
  56. 56.
    Murray N, Zheng YC, Mandel G, Brehn P, Bolinger R, Reuer Q, Kullbergh R. A single site on the ??subunit is responsible for the change in Ach receptor channel conductance during skeletal muscle development. Neuron 1995;14:865–70.Google Scholar
  57. 57.
    Moscoco LM, Chu GC, Gautam M, Noakes PG, Merlie JP, Danes JR. Synapse-associated expression of an acetylcholine receptor-inducing protein. ARIA/Hergulin, and its putative receptors, ErbB2 and ErbB3, in developing mammalian muscle. Devel Biol 1995;172:158–69.Google Scholar
  58. 58.
    Steinbach JG, Ifune C. How many kinds of nicotinic acetylcholine receptors are there? Trends Neurosci. 1989;12:3–6.Google Scholar
  59. 59.
    Anderson DG, Blobel G. In vitro synthesis, glycosylation and membrane insertion of the four subunits of Torpedo acetylcholine receptor. Proc Natl Acad Sci USA 1981;78:5598–602.Google Scholar
  60. 60.
    McCrea PD, Popot K, Engelman DM. Transmembrane topography of the nicotinic acetylcholine receptor delta subunit. EMBO J 1987;6:1319–26.Google Scholar
  61. 61.
    Levitt TA, Salpeter MM. Denervated endplates have a dual population of junctional acetylcholine receptors. Nature 1981;291:239–41.Google Scholar
  62. 62.
    Fontaine B, Klarsfeld A, Changeux JP. Calcitonin gene-related peptide and muscle activity regulate acetylcholine receptor a-subunit mRNA levels by distinct intracellular pathways. J Cell Biol 1987:1337–42.Google Scholar
  63. 63.
    Markelonis GJ, Oh TO, Derr D. Stimulation of protein synthesis in cultered skeletal muscle by a trophic protein from sciatic nerves. Exp Neurol 1980;70:598–612.Google Scholar
  64. 64.
    McMahan UJ, Horton SE, Werle MJ, Honig LS, Kroger S, Ruess MA, Escher G. Agrin isoforms and their role in synaptogenesis. Curr Opin Cell Biol 1992;4:869–74.Google Scholar
  65. 65.
    Patrick J, Séquéla P, Vernino S, Amador M, Luetje C, Dani JA. Functional diversity of neuronal nicotinic acetylcholine receptors. Prog Brain Res 1993;98:113–20.Google Scholar
  66. 66.
    Apel ED, Roberds SL, Campbell KP, Merlie JP. Rapsyn may function as a link between the acetylcholine receptor and the agrin-binding dystrophin-associated glycoportein complex. Neuron 1995;15:115–26.Google Scholar
  67. 67.
    Dwyer TM, Adams DJ, Hille B. The permeability of the end-plate channel to organic cations in frog muscle. J Gen Physiol 1980;75:469–92.Google Scholar
  68. 68.
    Klymkowsky MW, Stroud RM. Immunospecific identification and three dimensional structure of a membrane-bound acetylcholine receptor Torpedo californica. J Mol Biol 1979; 128:319–34.Google Scholar
  69. 69.
    Mitra AK, McCarthy MP, Stroud RM. Three dimensional structure of the nicotinic acetylcholine receptor and location of the major associated 43-kD cytoskeletal protein, determined at 22 å by low dose electron microscopy and x-ray diffraction to 12.5 å. J Cell Biol 1989;109:755–74.Google Scholar
  70. 70.
    Cash DJ, Hess GP. Molecular mechanisms of acetylcholine receptors-controlled ion translocation across cell membranes. Proc Natl Acad Sci USA 1980;77:842–46.Google Scholar
  71. 71.
    Raftery MA, Conti-Tronconi BM, Dunn SMJ. Structural and functional aspects of the nicotinic acetylcholine receptor. Fund Appl Toxicol 1985;5:S39–S46.Google Scholar
  72. 72.
    Smith MM, Lindstrom J, Merlie JP. Formation of the a-bungarotoxin binding site and assembly of the nicotinic acetylcholine receptor subunits occurs in the endoplasmic reticulum. J Biol Chem 1987;262:4367–76.Google Scholar
  73. 73.
    Devreotes PN, Gardner JM, Fambrough DM. Kinetics of biosynthesis of acetylcholine receptor and subsequent incorporation into plasma membrane of cultured chick skeletal muscle. Cell 1977;10:365–73.Google Scholar
  74. 74.
    Merlie JP, Isenberg K, Carlin B, Olson EN. Regulation of syntyhesis of acetylcholine receptors. Trends Pharmacol Sci 1984;377–9.Google Scholar
  75. 75.
    Merlie JP, Isenberg KE, Russell SD, Sanes JR. Denervation supersensitivity in skeletal muscle: Analysis with a cloned cDNA probe. J Cell Biol 1984 99:332–5.Google Scholar
  76. 76.
    Illingworth JA. Muscle biochemistry. Br J Anaesth 1980;52: 123–8.Google Scholar
  77. 77.
    Floyd K. The physiology of striated muscle. Br J Anaesth 1980;52:111–21.Google Scholar
  78. 78.
    Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol (Lond) 1967;191:59.Google Scholar
  79. 79.
    Paton WD, Waud DR. The margin of safety of neuromuscular transmission. J Physiol (Lond) 1967;191:59–90.Google Scholar
  80. 80.
    Robinson DS, McGee R. Agonist-induced regulation of the neuronal nicotinic acetylcholine receptor of PC12 cells. Mol Pharmacol 1985;27:409–17.Google Scholar
  81. 81.
    Berg DK, Boyd RT, Halvorsen SW, Higgins LS, Jacob MK, Margiotta F. Regulating the number and function of neuronal acetylcholine receptors. Trends Neurosci 1989;12:16–26.Google Scholar
  82. 82.
    Benwell MEM, Balfour DJK, Anderson JM. Evidence that tobacco smoking increases the density of (-)-[3H]nicotine binding sites in human brain. J Neurochem 1988;50:12437.Google Scholar
  83. 83.
    Wonnacott S. The paradox of nicotinic acetylcholine receptor upregulation by nicotine. Trends Pharmacol Sci 1990;11: 216–9.Google Scholar
  84. 84.
    Schwartz RD, Kellar KJ. In vivo regulation of [sH]acetylcholine recognition sites in brain by nicotinic cholinergic drugs. J Neurochem 1985;42:483–91.Google Scholar
  85. 85.
    Costa LG, Murphy SD. [3H]Nicotinic binding in rat brain: alteration after chronic acetylcholine esterase inhibition. J Pharmacol Exp Ther 1983;226:392–7.Google Scholar
  86. 86.
    Martyn JAJ, White DA, Gronert GA, Jaffe RS, Ward JM. Upand-down regulation of skeletal muscle acetylcholine receptors. Anesthesiology 1992;76:822–43.Google Scholar
  87. 87.
    Hogue Jr, CW, Ward JM, Itani MS, Martyn JAJ. Tolerance and upregulation of acetylcholine receptors follow chronic infusion of d-tubocurarine. J Appl Physiol 1992;72:1326–31.Google Scholar
  88. 88.
    Horton WA, Fergusson NV. Hyperkalemia and cardiac ar rest after the use of suxamethonium in intensive care. Anaesthesia 1988;43:890–1.Google Scholar
  89. 89.
    Laylock JRD, Loughman E. Suxamethonium-induced hyperkalemia following cold injury. Anaesthesia 1986;41:739–41.Google Scholar
  90. 90.
    Gupta RS, Dettborn WD, Patterson GT. Mechanisms of toxicity and tolerance to disopropylphosphoro-fluoridate at the neuromuscular junction. Toxicol Appl Pharmacol 1986;84: 541–50.Google Scholar
  91. 91.
    Wessler I. Control of transmitter release from the motor nerve by presynaptic nicotinic and muscarinic autoreceptors. Trends Pharmaco Sci 1989;10:110–14.Google Scholar
  92. 92.
    Prior C, Tian L, Dempster J, Marshall IG. Prejunctional actions of muscle relaxants: synaptic vesicles and transmitter mobilization as sites of action. Gen Pharmacol 1995;26:659–66.Google Scholar
  93. 93.
    Bowman WC. Prejunctional and postjunctional cholinoceptors at the neuromuscular junction. Anesth Analg 1980;59: 935–43.Google Scholar
  94. 94.
    Foldes FF, Chaudry IA, Kinjo M, Nagashima H. Inhibition of mobilization of acetylcholine. Anesthesiology 1989;71:218–23.Google Scholar
  95. 95.
    Bowman WC, Prior C, Marshall IG. Presynaptic receptors in the neuromuscular junction. Ann NY Acad Sci 1990;604: 69–81.Google Scholar
  96. 96.
    Williams NE, Webb SN, Calvey TN. Differential effects of myoneural blocking drugs on neuromuscular transmission. Br J Anaesth 1980;52:1111–14.Google Scholar
  97. 97.
    Tian L, Prior C, Dempster J, Marshall IG. Nicotinic antagonist-produced frequency-dependent changes in acetylcholine release from rat motor nerve terminals. J Physiol (Lond) 1994;476:517–29. 10.Google Scholar
  98. 98.
    Wilson DF, Thomsen RH. Effects of hexamethonium on transmitter release from the rat phrenic nerve. Neurosci Letters 1992;143:79–82.Google Scholar
  99. 99.
    Silinsky EM. The biophysical pharmacology of calciumdependent acetylcholine secretion. Pharmac Rev 1985;37: 81–132.Google Scholar
  100. 100.
    Meldolesi J, Scheer H, Madeddu L. Mechanism of action of a-latrotoxin: the presynaptic stimulatory toxin of the black widow spider venom. Trends Pharmacol Sci 1986;7:151–155.Google Scholar
  101. 101.
    Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972;37:413–16.Google Scholar
  102. 102.
    Bowman WC. Physiology and pharmacology of neuromuscular transmission, with special reference to the possible consequences of prolonged blockade. Intens Care Med 1993;19:S45–S53.Google Scholar
  103. 103.
    Shanks CA, Somogyi AA, Triggs EJ. Dose-response and plasma concentration-response relationship of pancuronium in man. Anesthesiology 1979;51:111–18.Google Scholar
  104. 104.
    Agoston S, Feldman SA, Miller RD. Plasma concentrations of pancuronium and neuromuscular blockade after injection into isolated arm, bolus injection, and continuous infusion. Anesthesiology 1979;51:119–22.Google Scholar
  105. 105.
    Shanks CA, Somogyi AA, Triggs EJ. Plasma concentrations of pancuronium during pre-determined intensities of neuromuscular blockade. Br J Anaesth 1978;235–8.Google Scholar
  106. 106.
    Stanski DR, Sheiner LB. Pharmacokinetics and dynamics of muscle relaxants. Anesthesiology 1979;51:103–5.Google Scholar
  107. 107.
    Lambert JJ, Durant NN, Henderson EG. Drug-induced modifications of ionic conductance at the neuromuscular junction. Ann Rev Pharmacol Toxicol 1983;23:505–39.Google Scholar
  108. 108.
    Thesleff S. the mode of neuromuscular block caused by acetylcholine, nicotine, decamethonium and succinylcholine. Acta Physiol Scand 1955;34:218–31.Google Scholar
  109. 109.
    Unwin N, Toyoshima C, Kubalek E. Arrangement of the acetylcholine receptor subunits in the resting and desensitized states, determined by cryoelectron microscopy of crystallized Torpedo postsynaptic membranes. J Cell Biol 1988; 107:1123–38.Google Scholar
  110. 110.
    Wachtel RE. Comparison of anticholinesterases and their effects of acetylcholine-activated ion channels. Anesthesiology 1990;70:405–10.Google Scholar
  111. 111.
    Payne JP, Hughes R, Al Azawi S. Neuromuscular blockade by neostigmine in anaesthetized man. Br J Anaesth 1980;52: 69–76.Google Scholar
  112. 112.
    Waud BE, Waud DR. The margin of safety of neuromuscular transmission in the muscle of the diaphragm. Anesthesiology 1972;37:413–16.Google Scholar
  113. 113.
    Bovet D, Depoierre F, Lestrange Y. Proprietes curarisantes des ethers phenoliques a fonctions ammonium quarternaires. Comptes Rendus Hebdomadaires de Sceances de l'Academie des Sciences 1947;225:74–76.Google Scholar
  114. 114.
    Lund I, Stovner J. Experimental and clinical experiences with a new muscle relaxant RO 4-3816, diallyl-nortoxiferine. Acta Anaesthesiol Scand 1962;62:85–97.Google Scholar
  115. 115.
    Baird WLM, Reid AM. The neuromuscular blocking properties of a new steroid compound, pancuronium bromide. Br J Anaesth 1967;39:775–80.Google Scholar
  116. 116.
    Sobell HM, Sakore TD, Tavale SS, Canepa FG, Pauling P, et al. Stereochemistry of curare alkaloid: O,O',N-trimethyl-dtubocurarine. Proc Natl Acad Sci USA 1972;69:2212–15.Google Scholar
  117. 117.
    Kimenis A, Klusha VE, Ginters YA. Pharmacology of Dioxonium, a new myorelaxant. Farmakologiya i toxicologiya 1972;35:172.Google Scholar
  118. 118.
    Simpson BR, Strunin L, Savege TM, Walton B, Foley ET, Maxwell MP, et al. An azobis-arylimidazo-pyridinium derivative: A rapidly acting non-depolarizing muscle-relaxant. Lancet 1972;1:516–19.Google Scholar
  119. 119.
    Marshall IG, Agoston S, Booij LHDJ, Durant NN, Foldes FF. Pharmacology of Org NC45 compared with other nondepolarizing neuromuscular blocking drugs. Br J Anaesth 1980;52:11S–19S.Google Scholar
  120. 120.
    Crul JF, Booij LHDJ. First clinical experiences with Org NC45. Br J Anaesth 1980;52suppl:S49–52S.Google Scholar
  121. 121.
    Wierda JMKH, Richardson FJ, Agoston S. Dose response relation and time course of action of pipecuronium bromide in humans anaesthetized with nitrous oxide and isoflurane, halothane, or droperidol/fentanyl. Anesth Analg 1989;68: 208–13.Google Scholar
  122. 122.
    Payne JP, Hughes R. Evaluation of atracurium in anaesthetized man. Br J Anaesth 1981;53:45–54.Google Scholar
  123. 123.
    Basta SJ, Ali HH, Savarese JJ, Sunder N, Gionfriddo M, Cloutier G, Lineberry C, Cato AE. Clinical pharmacology of atracurium besylate (BW 33A): A new non-depolarizing muscle relaxant. Anesth Analg 1982;61:723–9.Google Scholar
  124. 124.
    Basta SWJ, Savarese JJ, Ali HH, Embree PB, Schwartz AF, Rudd GD, Wastlla WB. Clinical pharmacology of doxacurium chloride. Anesthesiology 1988;69:478–86.Google Scholar
  125. 125.
    Savarese JJ, Ali HH, Basta SJ, Embree PB, Scott RPF, Sunder N, Weakly JN, Wastlla WB, el-Sayad HA. The clinical neuromuscular pharmacology of mivacurium chloride (BW 1090U): A short acting ester neuromuscular blocking drug. Anesthesiology 1988;68:723–32.Google Scholar
  126. 126.
    Booij LHDJ, Knape JTA. The neuromuscular blocking effect of Org 9426. Anaesthesia 1991;46:341–3.Google Scholar
  127. 127.
    Gyermek L. Nguyen N, Lee C. GI-64, a new, rapidly acting nondepolarizing neuromuscular blocking agent. Anesthesiology 1990;73:A862.Google Scholar
  128. 128.
    Kharkevich DA. New curare-like agents. J Phar Pharmac 1974;26:153–65.Google Scholar
  129. 129.
    Gandiha A, Marshall IG, Paul D, Rodger IW, Scott W, Singh H. Some actions of chandonium iodide, a new short-acting muscle relaxant, in anesthetized cats and on isolated muscle preparations. Clin Exp Pharmacol Physiol 1975;2:150–70.Google Scholar
  130. 130.
    Baird WLM. Initial studies in man with a new myoneural blocking agent (Org 6368). Br J. Anaesth 1974;46:658–61.Google Scholar
  131. 131.
    Booij LHDJ, Crul JF, van der Pol F. Cardiovascular and neuromuscular blocking effects of four new muscle relaxants in anaesthetized Beagle dogs. Eur J Anaesthesiol 1988;6:70.Google Scholar
  132. 132.
    Muir AW, Houston J, Marshall RJ, Bowman WC, Marshall IG. A comparison of the neuromuscular blocking and autonomic effects of two new short-acting muscle relaxants with those of succinylcholine in the anesthetized cat and pig. Anesthesiology 1989;70:533–40.Google Scholar
  133. 133.
    Gilly H, Hirtschl MM, Steinbereithner K. Pharmacodynamics of Org 8764, atracurium and vecuronium: a comparison of vocal cord, diaphragm and tibial muscle relaxation. Anesthesiology 1988;69;A481.Google Scholar
  134. 134.
    Muir AW, Anderson K, Marshall RJ, Booij LHDJ, Crul JF, Prior C, Bowman WC, Marshall IG. The effects of a 16-N-homopiperidino analogue of vecuronium on neuromuscular transmission in anaesthetized cats, pigs, dogs an monkeys, and in isolated preparations. Acta Anaesthesiol Scand 1991;35:85–90.Google Scholar
  135. 135.
    Hughes R. Evaluation of the neuromuscular blocking properties and side-effects of the two new isoquinolinium bisquarternary compounds (BW 252C64 and BW 403C65). Br J Anaesth 1972;44:27–42.Google Scholar
  136. 136.
    Kimura M, Kimura I, Muroi M, Nojima H, Diwan PV. Depolarizing neuromuscular blocking action of coryneine derived from aconite root in isolated phrenic nerve-diaphragm muscles. Biol Pharm Bull 1995;18:691–5.Google Scholar
  137. 137.
    Tammisto T, Salmenpera M. Neuromuscular blocking properties of dioxonium. Acta Anaesth.Scand. 1980;24:439–43.Google Scholar
  138. 138.
    Salmenpera M, Tammisto T. The use of dioxonium as a neuromuscular blocking agent. Acta Anaesth Scand 1980;24: 395–8.Google Scholar
  139. 139.
    Bowman WC, Rodger IW, Houston J, Marshall RJ, McIndewar I. Structure: action relationships among some desacetoxy analogues of pancuronium and vecuronium in the anesthetized cat. Anesthesiology 1988;69:57–62.Google Scholar
  140. 140.
    Maehr RB, Wastila WB. Comparative pharmacology of atracurium and six isomers in cats. Anesthesiology 1993;79: A946.Google Scholar
  141. 141.
    Law Min JC, Bakavac I, Glavinovic MI, Donati F, Bevan DR. Iontophorectic study of speed of action of various muscle relaxants. Anesthesiology 1992;77:351–6.Google Scholar
  142. 142.
    Kim SY, Hwang KH, Ok SY, Kim SI, Kim SC, Park W. Discrepancy of recovery times related to potency between atracurium and mivacurium simultaneously administered in isolated forearms. Anaesthesia 1995;50:507–9.Google Scholar
  143. 143.
    Kopman AF. Pancuronium, gallamine and d-tubocurarine compared: is speed of onset inversely related to drug potency? Anesthesiology 1989;70:915–20.Google Scholar
  144. 144.
    Ramzan IM. Molecular weight of cation as a determinant of speed of onset of neuromuscular blockade. Anesthesiology 1982;57:247–48.Google Scholar
  145. 145.
    Blackburn CL, Morgan M. Comparison of speed of onset of fazadinium, pancuronium, tubocurarine and suxamethonium. Br J Anaesth 1978;50:361–4.Google Scholar
  146. 146.
    Mirakhur RK, Lavery GG, Clarke RSJ, Gibson FM, McAtees E. Atracurium in clinical anaesthesia: effect of dosage on onset, duration and conditions for tracheal intubation. Anaesthesia 1985;40:801–5.Google Scholar
  147. 147.
    Feldman S, Fauvel N, Harrop-Griffiths W. The onset of neuromuscular blockade. In: Bowman WC, Denissen PAF, Feldman S, eds. Neuromuscular blocking agents: past, present and future. Amsterdam: Excerpta Medica 1990 pp. 44–51.Google Scholar
  148. 148.
    Ginsberg B, Glass PS, Quill T, Shafron D, Ossey KD: Onset and duration of neuromuscular blockade following highdose vecuronium administration. Anesthesiology 1989;71: 201–5.Google Scholar
  149. 149.
    Tullock WC, Diana P, Cook DR, Wilks DH, Brandom SW, Stiller RL, Beach CA. Neuromuscular and cardiovascular effects of high-dose vecuronium. Anesth Analg 1990;70:86–90. 11.Google Scholar
  150. 150.
    Glass PSA, Wilson W, Mace JA, Wagoner R: Is the priming principle both effective and safe? Anesth. Analg. 1989;68: 127–34.Google Scholar
  151. 151.
    Mirakhur RF, Lavery GG, Gibson FM, Clarke RS. Intubating conditions after vecuronium and atracurium given in divid-ed doses (the priming principle). Acta Anaesthesiol Scand 1986;30:347–50.Google Scholar
  152. 152.
    Sosis M, Stiner A, Larijari GE, Marr AT. An evaluation of priming with vecurionium. Br J Anaesth 1987;59:1236–9.Google Scholar
  153. 153.
    Waud BE, Waud DR. Quantitative examination of the interaction of competitive neuromuscular blocking agents on the indirectly elicited twitch. Anesthesiology 1984;61:420–7.Google Scholar
  154. 154.
    Naguib M. Neuromuscular effects of rocuronium bromide and mivacurium chloride administered alone and in combination. Anesthesiology 1994;81:388–95.Google Scholar
  155. 155.
    Wood M. Plasma drug binding: implications for anaesthesiologists. Anesth Analg 1986;65:786–804.Google Scholar
  156. 156.
    Karalliedde L. Animal toxins. Br.J.Anaesth. 1995;74:319–27.Google Scholar
  157. 157.
    Schiavo G, Rossetto O, Montecucco C. Clostridial neurotoxins as tools to investigate the molecular events of neurotransmitter release. Semin Cell Biol 1994;5:221–9.Google Scholar
  158. 158.
    Henkel AW, Betz WJ. Monitoring of Black Widow Spider venom (BWSV) induced exo-and endocytosis in living frog motor nerve terminals with FM1-43. Neuropharmacol 1995;1397–1406.Google Scholar
  159. 159.
    Abramson SN, Febical W, Taylor P. Lophotoxins: irreversible active-site directed inhibitors of nicotinic acetylcholine receptors. Drug Devel Res 1991;24:297–312.Google Scholar

Copyright information

© Kluwer Academic Publishers 1997

Authors and Affiliations

  • L.H.D.J. Booij
    • 1
  1. 1.Department of AnaesthesiologyCatholic University NijmegenNijmegenThe Netherlands

Personalised recommendations